Basal-Bolus Insulin Regimen for DKA
After DKA resolution, transition to a basal-bolus regimen using 50% of total daily dose (TDD) as basal insulin (given once or twice daily) and 50% as rapid-acting insulin divided before meals, with the TDD calculated from the average hourly IV insulin rate over the 12 hours before transition multiplied by 24. 1
Calculating the Transition Dose
When transitioning from IV insulin to subcutaneous therapy after DKA resolution:
- Calculate TDD: Take the average hourly IV insulin infusion rate from the 12 hours before transition and multiply by 24
- Example: If receiving 1.5 units/hour → TDD = 36 units/day 1
- Split the dose: 50% basal + 50% prandial (bolus) 1
Specific Regimen Structure
Basal insulin component:
- Give 50% of TDD as long-acting basal insulin (glargine or detemir)
- Administer once or twice daily 1
- Critical timing: Give basal insulin 2-4 hours before stopping IV insulin to prevent rebound hyperglycemia and recurrent ketoacidosis 2
Bolus insulin component:
- Give 50% of TDD as rapid-acting insulin (lispro, aspart, or glulisine)
- Divide equally among three meals (approximately 16-17% of TDD per meal) 1
- Add correctional doses of rapid-acting insulin as needed 1
Evidence-Based Advantages
A basal-bolus regimen with glargine and glulisine after DKA resolution results in similar glycemic control but significantly lower hypoglycemia rates compared to NPH and regular insulin (41% vs 15% hypoglycemia rate, P=0.03). 3 This makes the analog-based basal-bolus approach safer and preferred over older insulin formulations.
Emerging Evidence: Early Basal Insulin
Recent high-quality evidence suggests administering basal insulin during active DKA treatment (not just after resolution):
- Early subcutaneous basal insulin combined with IV insulin significantly reduces time to DKA resolution by approximately 4 hours (MD -4.06 hours, 95% CI -5.53 to -2.58; p<0.0001) 4
- Reduces total IV insulin requirements and fluid needs 5, 4, 6
- Does not increase hypoglycemia or hypokalemia risk 4, 6
- The Joint British Diabetes Societies guidelines (updated 2023) now advocate for early basal insulin administration 6, 7
Important Caveats
Avoid sliding scale insulin alone in patients with type 1 diabetes—this is inadequate and condemned in guidelines 1. The basal-bolus approach reduces complications including wound infections, pneumonia, bacteremia, and renal/respiratory failure compared to reactive insulin-only strategies 1.
For patients at high hypoglycemia risk (elderly >65 years, renal failure, poor oral intake): Use lower initial doses (0.3 units/kg rather than 0.5 units/kg for TDD calculation) 1.
Monitor closely: Blood glucose should be checked at least every 2-4 hours initially, with adjustments made to prevent both hyperglycemia and hypoglycemia 2.